Related Experiment Video
Updated: Jun 14, 2025
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
The aspirin heart disease prevention conundrum
H Robert Superko1, John Sninsky1, Brenda Garrett1
1Cholesterol, Genetics and Heart Disease Institute (501c3 nonprofit), USA.
Insights
Genetic testing for LPA variants can identify individuals who benefit most from aspirin for primary cardiovascular prevention. Aspirin use in these individuals significantly reduces coronary heart disease events without increasing bleeding risk.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pharmacogenomics
Background:
- Daily aspirin use for primary prevention of cardiovascular disease (CVD) presents a dilemma due to balanced risks of CVD event reduction and gastrointestinal (GI) bleeding.
- Lipoprotein (a) [LPA] is a key risk factor for atherosclerotic cardiovascular disease.
- Genetic variations in LPA may influence individual responses to aspirin therapy.
Purpose of the Study:
- To investigate the role of LPA polymorphisms in identifying patients who benefit from primary aspirin prophylaxis.
- To determine if LPA variant carriers experience differential cardiovascular event reduction with aspirin compared to non-carriers.
Main Methods:
- Analysis of clinical trial data focusing on the LPA variant rs3798220.
- Comparison of coronary heart disease (CHD) event rates in carriers and non-carriers of the LPA variant, with and without aspirin treatment.
Main Results:
- Carriers of the LPA variant (rs3798220) exhibit a higher risk of CHD events compared to non-carriers.
- Aspirin treatment significantly reduced major CHD events in LPA variant carriers to levels comparable to non-carriers.
- The cardiovascular benefits of aspirin in carriers outweigh the increased risk of serious GI bleeding.
Conclusions:
- Genetic testing for LPA variants can personalize aspirin therapy for primary CVD prevention.
- Identifying LPA variant carriers allows for targeted aspirin use, maximizing cardiovascular risk reduction.
- This approach offers an inexpensive strategy to optimize primary prevention for specific patient populations.
Abstract:
The use of daily aspirin in a primary prevention population to reduce cardiovascular disease event risk is a conundrum because the reduction in cardiovascular event risk is balanced by an equal increase in the risk of a serious gastrointestinal bleed. This conundrum can be partially clarified by genetic testing for LPA polymorphisms. A genetic polymorphism in the apolipoprotein (a) component of lipoprotein (a) has been identified that could help identify patients who may benefit the most from daily aspirin in regard to coronary heart disease event reduction. Recent clinical trials have demonstrated that carriers of the LPA variant (rs3798220) have a significantly greater risk for a coronary heart disease event compared to non-carriers. However, in carriers of the LPA variant randomized to aspirin, the incidence of major coronary heart disease events was reduced to the same level as subjects who did not have the LPA variant. This provides a clinically available tool that may allow identification of a subset of primary prevention patients who derive more cardiovascular risk reduction from daily aspirin than the risk of a serious gastrointestinal bleed. This provides an inexpensive treatment options for patients with the LPA variant.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....